||The CEBPA mutation assay was designed to assist clinicians in determining prognosis in cytogenetically normal acute myeloid leukemia (AML). CEBPA mutations have been identified in a subset of AML patients (5-14%) and appear to confer a favorable prognosis. With continued study, the specific clinical characteristics of patients with CEBPA mutations are becoming increasingly clear.
DNA isolated from the patient’s sample is amplified by polymerase chain reaction (PCR) using four primer sets spanning the gene. The resulting PCR products are then sequenced using capillary gel electrophoresis and fluorescence detection.